Treatment of Chronic Hepatitis C Virus Infection with Recombinant Consensus Interferon
| Autor: | Kenneth J. Resser, Kohar Sayadzadeh, Tracy Figueroa, Michael C. Klein, Myron J. Tong, Scott E. Cruickshank, Lawrence M. Blatt |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Adolescent Immunology Consensus interferon Hepacivirus Virus Chronic hepatitis Virology Consensus Sequence Humans Medicine Aged Dose-Response Relationship Drug business.industry Alanine Transaminase Cell Biology Hepatitis C Chronic Middle Aged Recombinant Proteins Liver Interferon Type I RNA Viral Female business Recombinant Consensus Interferon |
| Zdroj: | Journal of Interferon & Cytokine Research. 18:81-86 |
| ISSN: | 1557-7465 1079-9907 |
| DOI: | 10.1089/jir.1998.18.81 |
| Popis: | To assess the safety and efficacy of consensus interferon (IFN-Con-1), 55 patients with chronic hepatitis C infection were treated with either 3, 6, 9, 12, or 15 microg IFN-Con-1 s.c. three times a week for 24 weeks, followed by 24 weeks of observation. There was a dose-response relationship with respect to the number of patients with normalized ALT concentrations or undetectable HCV RNA. At the end of the 24-week treatment period, the serum ALT had normalized in 18% of patients given the 3 microg dose and 42% of patients given the 12 microg or 15 microg doses of IFN-Con-1. At the end of the posttreatment observation period, the serum ALT was still normal in 10% of patients given the 3 microg, 6 microg, or 9 microg doses and in 50% of patients given the 15 microg dose. Also, at the end of the 24-week treatment period, 27% of patients given the 3 microg dose and 75% given the 15 microg dose had undetectable serum HCV RNA. At the end of the posttreatment observation period, the proportion of patients with undetectable HCV RNA ranged from 9% of those given the 3 microg dose to 50% of those given the 15 microg dose. Our study indicates that treatment with IFN-Con-1 appears to be safe and effective. In addition, use of 15 microg of IFN-Con-1 resulted in significantly more patients with sustained ALT normalization and absence of HCV RNA 6 months after cessation of therapy compared with treatment with lower doses of IFN-Con-1. Additional trials are underway to confirm these findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|